Week Ending September 26, 2022

Immunotherapy for Non-Small-Cell Lung Cancer with Unresectable Stage III
“Concurrent chemoradiotherapy (CCRT) and adjuvant durvalumab are the recommended treatments for people with stage III non-small-cell lung cancer (NSCLC). However, despite the increased chance of survival provided by immunotherapy in this situation, just one-third of patients were alive and disease-free at 5 years.”

Squamous Cell Carcinoma of the Lung: Treatment Considerations
“The researchers found that squamous cell carcinoma (SCC) of the lung is a subtype of non-small cell lung cancer (NSCLC) with a distinct molecular profile distinguishing it from adenocarcinoma of the lung. There was a critical unmet need for efficient second-line options following immunotherapy, especially as immune checkpoint inhibitors are being rapidly elevated from second to first-line status in NSCLC.”

A Guide to Lung Cancer Symptoms
“Lung cancer occurs when atypical cells in the lungs grow and multiply uncontrollably. This can cause various symptoms. If you experience any of the symptoms of lung cancer, speak with your doctor right away.”

Cancer survival rate rises in the US
“In a recent article by the American Association for Cancer Research (AACR), the researchers highlighted basic, translational, and clinical cancer research and cancer-related population sciences in the 12th edition of its annual Cancer Progress Report.”

How Do Patients With Lung Cancer Report on the Quality of Care?
“Lung cancer is the second leading cancer type, with the American Cancer Society estimating approximately 236,740 new cases in 2022.”

The 50-Year Journey of Lung Cancer Screening: A Narrative Review
“Early diagnosis and treatment are associated with better outcomes in oncology. We reviewed the existing literature using the search terms “low dose computed tomography” and “lung cancer screening” for systematic reviews, metanalyses, and randomized as well as non-randomized clinical trials in PubMed from January 1, 1963 to April 30, 2022.”

Lung cancer treatment: Specific gene mutation may be a key
“Lung cancer can be both deadly and difficult to treat. Experts’ understanding of lung cancer has significantly expanded in recent years with developing new treatment options being a priority.”

Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in Care

Catherine A. Shu, MD, Reviews Findings of Cohort A of the Phase 1 CHRYSALIS-2 Trial in Pretreated EGFR+ NSCLC